Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company specializing in neuroscience, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat presentation on Wednesday, Sept. 4, 2024, at 2:35 p.m. EDT. Investors can access the live webcast on Alkermes' website under the Investors tab, where it will remain archived for 14 days.

Alkermes focuses on developing innovative medicines for neurological disorders, with a portfolio of commercial products treating conditions such as alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for various neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes maintains a corporate office and research center in Massachusetts and a manufacturing facility in Ohio.

News Market Reaction – ALKS

+1.00%

+1.00% Session move

In the trading session that priced this news, ALKS gained 1.00%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Aug. 28, 2024  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22^nd Annual Global Healthcare Conference on Wednesday, Sept. 4, 2024 at 2:35 p.m. EDT (7:35 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-302233183.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) participating in the Morgan Stanley Healthcare Conference?

Alkermes (ALKS) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 2:35 p.m. EDT.

How can investors access Alkermes' (ALKS) presentation at the Morgan Stanley conference?

Investors can access the live webcast of Alkermes' (ALKS) presentation under the Investors tab on www.alkermes.com. The webcast will be archived for 14 days after the event.

What are the main therapeutic areas Alkermes (ALKS) focuses on?

Alkermes (ALKS) focuses on neuroscience, developing treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and other neurological disorders including narcolepsy.

Where are Alkermes' (ALKS) main operational locations?

Alkermes (ALKS) is headquartered in Ireland, with a corporate office and research center in Massachusetts, and a manufacturing facility in Ohio.